Skip to main content

Advertisement

Table 4 Changes in ITSQ and PAM-D21 questionnaire scores

From: Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial

Variable, change from baseline LM25 (N = 80) IGL (N = 82)
Baseline Change from baseline Baseline Change from baseline
ITSQ, mean (SD)
 Inconvenience of regimen 92.7 (10.7) −1.5 (11.0) 92.2 (12.1) 0.5 (11.2)
 Lifestyle flexibility 82.9 (21.2) −0.1 (24.1) 84.7 (17.6) −4.8 (24.9)
 Glycemic control 80.9 (19.9) 6.9 (20.0) 78.3 (21.7) 10.3 (22.1)
 Hypoglycemic control 85.5 (14.7) −2.7 (17.7) 85.7 (17.8) 0.1 (17.0)
 Insulin delivery device satisfaction 86.9 (15.7) 4.2 (16.1) 88.6 (14.3) 1.1 (10.6)
 Total score 86.5 (11.4) 1.1 (11.6) 86.8 (12.4) 1.2 (10.6)
PAM-D21, mean (SD)
 Convenience/flexibility 90.0 (16.0) −0.7 (21.2) 91.7 (13.8) −1.2 (16.8)
 Perceived effectiveness 74.6 (20.7) 5.9 (23.7) 72.0 (20.5) 12.0 (25.4)
 Emotional effects 84.2 (20.2) 1.0 (21.7) 86.8 (17.5) −0.2 (22.4)
 Physical effects 87.0 (13.4) 1.0 (12.8) 90.5 (12.9) 1.1 (10.4)
  1. IGL once-daily basal insulin glargine plus once-daily prandial insulin lispro, ITSQ insulin treatment satisfaction questionnaire, LM25 75 % insulin lispro protamine suspension and 25 % insulin lispro solution, PAM-D21 perceptions about medications-diabetes 21, SD standard deviation